Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Evaluation of melatonin and AFMK levels in women with breast cancer

Full text
Author(s):
de Castro, Tialfi Bergamin [1] ; Bordin-Junior, Newton Antonio [2] ; de Almeida, Eduardo Alves [3] ; Pires de Campos Zuccari, Debora Aparecida [2, 1]
Total Authors: 4
Affiliation:
[1] Sao Paulo State Univ UNESP, Cristovao Colombo 2265, BR-15054000 Sao Paulo - Brazil
[2] Sao Jose do Rio Preto Med Sch FAMERP, Ave Brigadeiro Faria Lima 5416, BR-15090000 Sao Paulo - Brazil
[3] Reg Univ Blumenau Fdn FURB, Antonio da Veiga 140, BR-89030903 Blumenau, SC - Brazil
Total Affiliations: 3
Document type: Journal article
Source: ENDOCRINE; v. 62, n. 1, p. 242-249, OCT 2018.
Web of Science Citations: 3
Abstract

Purpose Changes in the circadian rhythm may contribute to the development of cancer and are correlated with the high risk of breast cancer (BC) in night workers. Melatonin is a hormone synthesized by the pineal gland at night in the absence of light. Levels of melatonin and the metabolite of oxidative metabolism AFMK (acetyl-N-formyl-5-methoxykynurenamine), are suggested as potential biomarkers of BC risk. The aims of this study were to evaluate levels of melatonin and AFMK in women recently diagnosed with BC, women under adjuvant chemotherapy, and night-shift nurses, and compare them with healthy women to evaluate the relation of these compounds with BC risk. Methods Blood samples were collected from 47 women with BC, 9 healthy women, 10 healthy night shift nurses, and 6 patients under adjuvant chemotherapy. Compound levels were measured by mass spectrometry. Results and conclusions Our results showed that women with BC had lower levels of melatonin compared to control group women, and even lower in night-shift nurses and in patients under adjuvant chemotherapy. There was no significant difference of AFMK levels between the groups. In addition to this, high levels of melatonin and AFMK were related to patients with metastasis, and high levels of AFMK were related to the presence of lymph node-positive, tumor > 20 mm and patients who sleep with light at night. Our results showed a reduction of melatonin levels in BC patients, suggesting a relation with the disease, and in addition, point to the importance of melatonin supplementation in women that work at night to reduce the BC risk. (AU)

FAPESP's process: 15/02935-2 - Melatonin and its metabolites as prognostic markers in human breast neoplasms
Grantee:Tialfi Bergamin de Castro
Support Opportunities: Scholarships in Brazil - Doctorate